[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-necrotizing-pancreatitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-necrotizing-pancreatitis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,72,95],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":5},"100626914","phase-3-pancreatic-enzyme-replacement-in-acute-necrotizing-pancreatitis-100626914",false,"NCT07441824","Pancreatic Enzyme Replacement in Acute Necrotizing Pancreatitis","Effect of Pancreatic Enzyme Replacement Therapy in Patients With Acute Necrotizing Pancreatitis: A Multicenter Double Blinded Randomised Placebo Controlled Trial","PERiANP","Inclusion Criteria:\n\n* Patients diagnosed with AP according to the Revised Atlanta Classification diagnostic criteria\n* Index episode of acute pancreatitis with more than 50% pancreatic parenchymal necrosis and at least 5% loss of pre pancreatitis body weight at the time of screening\n* Within 6 weeks of onset of disease\n* Able to take food orally\n* Age 18-60 years\n* Both genders\n\nExclusion Criteria:\n\n* Underlying chronic pancreatitis\n* Recurrent acute pancreatitis\n* Pancreatic cancer\n* Patients being discharged with NJ tubes\n* Pregnancy and lactation\n* Inability to give informed consent.","ALL","18 Years","60 Years",{"count":21,"type":22},140,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","In this multicenter, double blinded, placebo-controlled, 1:1 parallel group RCT, the investigators propose to evaluate the impact of pancreatic exocrine replacement therapy on patients with acute necrotizing pancreatitis (ANP). The investigators will include patients of 18-60yrs age and both genders with \\>50% pancreatic parenchymal necrosis and at least 5% loss of body weight.\n\nThe primary outcome measure is percent change in body weight at 3 months after enrolment. The intervention will include pancreatic enzyme consisting of 25000 IU of lipase and similar appearing placebo.",[28,29],"Acute Necrotizing Pancreatitis","Pancreatic Exocrine Insufficiency",[31,32,33],"acute pancreatitis","pancrearic exocrine insufficiency","pancreatic enzyme replacement therapy","RECRUITING","2026-04-29",{"date":37,"type":38},"2026-05-05","ACTUAL",{"date":40,"type":38},"2026-04-10",{"date":42,"type":22},"2027-06",{"name":44,"class":45},"Asian Institute of Gastroenterology, India","OTHER",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":55,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100612420","effectiveness-of-endorotor-ped-system-versus-conventional-endoscopic-techniques-for-the-management-of-walled-off-pancreatic-necrosis-in-acute-necrotizing-pancreatitis-randomized-single-blinded-controlled-superiority-trial-and-cost-utility-analysis-100612420","NCT07253350","Effectiveness of Endorotor PED® System Versus Conventional Endoscopic Techniques for the Management of Walled-off Pancreatic Necrosis in Acute Necrotizing Pancreatitis: Randomized Single-blinded Controlled Superiority Trial and Cost-utility Analysis","ROTONEC","Inclusion Criteria:\n\n* Age≥18years\n* ASA\\\u003C5\n* CT scan less than 7 days old\n* Hospitalized for acute necrotizing pancreatitis, whatever the cause, and who have undergone drainage of pancreatic collections for the following indications according to the revised Atlanta criteria (infection, organ compression, persistent organ failure)\n* Have need for at least one DEN session despite endoscopic drainage (persistence of clinical symptoms or sepsis \\>48h after drainage with collection still visible)\n\nExclusion Criteria:\n\n* No endoscopic drainage in place for the management of WON\n* Have already had a DEN session (endoscopic or else) before screening for inclusion\n* Life-expectancy \\\u003C 1year (advanced cancer, etc)\n* Known haemostasis disorder (chronic thrombocytopenia, haemophilia, etc.)\n* Pregnant or breastfeeding woman\n* Subject deprived of freedom, subject under a legal protective measure\n* Non-affiliation to a social security regimen or CMU\n* Patient or person of confidence (if present at the time of inclusion) opposing the patient's participation in research\n* Subject already involved in another interventional clinical research",{"count":54,"type":22},64,[56],"NA","This is a national single-blinded prospective multicenter randomized (1:1) controlled trial, with two parallel arms, using a PROBE methodology, including patients with complicated acute necrotizing pancreatitis who require DEN of WON collection after endoscopic drainage. We will compare 2 groups: conventional DEN and DEN with Endorotor®. The study will be offered to all consecutive patients fulfilling the eligibility criteria after endoscopic drainage for WON. Since the time between drainage and the first necrosectomy session is usually at least 48 hours a period of at least 24h will be allowed for the patient to consider options to participate or not. Information and collection of informed consent will be done by an investigating physician.",[28],[60,61],"endoscopic necrosectomy","necrotic pancreatic collection","2026-01-28",{"date":64,"type":38},"2026-01-30",{"date":66,"type":38},"2026-01-20",{"date":68,"type":22},"2029-11",{"name":70,"class":45},"Assistance Publique - Hôpitaux de Paris",1,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":79,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":82,"phases":4,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":91,"leadSponsor":93,"locationsCount":4},"100616668","integrating-plasma-metagenomics-and-host-response-for-accurate-diagnosis-of-infected-pancreatic-necrosis-in-a-prospective-multicenter-cohort-of-acute-necrotizing-pancreatitis-100616668","NCT07308600","Integrating Plasma Metagenomics and Host Response for Accurate Diagnosis of Infected Pancreatic Necrosis in a Prospective Multicenter Cohort of Acute Necrotizing Pancreatitis","PROMOTE","Inclusion Criteria:\n\n1. Confirmed acute necrotizing pancreatitis (Revised Atlanta 2012) within 48 h of symptom onset\n2. Age ≥14 years\n3. Written informed consent\n\nExclusion Criteria:\n\n1. Invasive interventions including percutaneous catheter drainage (PCD) and surgical necrosectomy have already been performed prior to admission.\n2. Confirmed infection outside of pancreas, including pulmonary infection, urinary tract infection.\n3. Pregnancy .\n4. Acute recurrent pancreatitis","14 Years",{"count":81,"type":22},200,"OBSERVATIONAL","This study is being done to find a faster and more accurate way to tell whether the necrosis in patients with acute necrotizing pancreatitis (ANP) has become infected. In the absence of microbiological confirmation, clinicians often have to initiate empirical antibiotic therapy for suspected pancreatic infection-a practice supported by current guidelines but one that may contribute to antimicrobial resistance. In this study, the investigators will combine metagenomic next-generation sequencing (mNGS) which could improve the accuracy of infected pancreatic necrosis (IPN) diagnosis and host transcriptional response analysis which could discriminate infectious and noninfectious inflammatory syndromes. In a prospective, multicentre, cohort study, 200 consecutive patients ≥ 14 years with ANP will be enrolled at four tertiary hospitals from Novemeber 2025 to December 2026. If validated, this single-blood approach could enable early, pathogen-directed therapy, curtail unnecessary antibiotics and expedite surgical timing in ANP.",[28,85],"Infected Pancreatic Necrosis","NOT_YET_RECRUITING","2026-01-06",{"date":89,"type":38},"2026-01-08",{"date":64,"type":22},{"date":92,"type":22},"2026-12-30",{"name":94,"class":45},"Xiangya Hospital of Central South University",{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":102,"enrollmentInfo":103,"targetDuration":4,"studyType":23,"phases":105,"briefSummary":106,"conditions":107,"keywords":109,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":71},"100599146","a-study-to-evaluate-splenectomy-on-debridement-for-acute-necrotizing-pancreatitis-with-pancreatic-sinistral-portal-hypertension-100599146","NCT07080697","A Study to Evaluate Splenectomy on Debridement for Acute Necrotizing Pancreatitis With Pancreatic Sinistral Portal Hypertension","The Impact of Splenectomy on Debridement Efficacy, Perioperative Recovery, and Prognosis in Patients With Acute Necrotizing Pancreatitis Complicated by Pancreatic Sinistral Portal Hypertension","Inclusion Criteria:\n\n1. Age between 18 and 75 years.\n2. Acute necrotic pancreatitis complicated by pancreatic sinistral portal hypertension.\n3. Patients undergoing open debridement for infected pancreatic necrosis\n\nExclusion Criteria:\n\n1. Patients with pre-existing heart, lung, liver, kidney, or other organ failure prior to acute pancreatitis (AP).\n2. Patients with pre-existing conditions such as cirrhosis that may lead to portal hypertension prior to AP.\n3. Patients with pre-existing hematological diseases prior to AP.\n4. Patients undergoing laparoscopic or nephroscopic debridement.","75 Years",{"count":104,"type":22},66,[56],"This study is a prospective, single-center, randomized controlled trial focusing on patients with acute necrotizing pancreatitis (ANP) complicated by pancreatic sinistral portal hypertension (PSPH). The study aims to study the impact of total splenectomy on the debridement efficacy, perioperative recovery, and prognosis of patients with ANP complicated by PSPH.",[28,108],"Portal Hypertension",[28,110,111,112],"Pancreatic Sinistral Portal Hypertension","Debridement","Splenectomy","2025-07-20",{"date":115,"type":38},"2025-07-23",{"date":117,"type":22},"2025-07-30",{"date":119,"type":22},"2028-02-29",{"name":121,"class":45},"Zhejiang University"]